BioregulatorPreclinicalAnimal Studies

Ovagen

Also known as Glu-Asp-Leu, EDL

A tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.

Preclinical research, approved in Russia as supplement

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-20 mg daily

Frequency

Once or twice daily

Duration

10-30 day cycles

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-20 mg daily via Oral capsules or sublingual, Once or twice daily. Dose range: 10-20 mg daily. Duration: 10-30 day cycles.

Timing & Administration

Administer via Oral capsules or sublingual. Frequency: Once or twice daily.

Mechanism of Action

Interacts with intracellular regulatory systems, modulating chromatin structure and transcription-factor accessibility. Influences cellular proliferation, extracellular matrix organization, and mucosal signaling.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical research, approved in Russia as supplement.

Side Effects & Safety

Important Warnings

  • Limited human data
  • Not FDA approved.
Generally well-tolerated
limited safety data outside Russia

References

No references available.